Clinical Trial Update: PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9 [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating PET imaging agents 64Cu-Tz-SarAr and hu5B1-TCO in pancreatic, colorectal, and bladder cancers (including cancers with elevated CA19-9) …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Colorectal Cancer
• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• 64Cu-Tz-SarAr
• hu5B1-TCO

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 | Status: WITHDRAWN